Clinical Trial Update: Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating panitumumab with paclitaxel, carboplatin and 5-FU in potentially resectable gastroesophageal adenocarcinoma; the study was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Distal Esophagus
• Adenocarcinoma of the Gastroesophageal Junction
• Adenocarcinoma of the Proximal Stomach
• Gastroesophageal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Panitumumab (panitumumab)

Snippet

Sponsor: Accelerated Community Oncology Research Network | Conditions: Gastroesophageal Adenocarcinoma, Adenocarcinoma of the Distal Esophagus | Phase 2 | Status: TERMINATED | Results posted: 2012-11-28